Please assess the completion status of the following clinical trial:

Trial Title: Complement Inhibition in aHUS Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years;~* Diagnosis of aHUS with or without identified genetic abnormalities in the complement system or thrombomodulin;~* Stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months;~* Written informed consent.~Exclusion Criteria:~* Women of childbearing potential or women who are breastfeeding;~* Shiga toxin-associated HUS or secondary forms of thrombotic microangiopathy;~* ADAMTS13 activity \<10 % or circulating anti ADAMTS13 autoantibodies consistent with the diagnosis of thrombotic thrombocytopenic purpura;~* Need for specific intervention with plasma therapy and/or complement inhibitors as deemed clinically appropriate;~* Plasma therapy or treatment with complement inhibitors or antiplatelet and antithrombotic agents over the last two weeks;~* Liver function impairment (serum liver enzymes or bilirubin levels \>3 x upper limit of normal);~* Neutrophil count \< 2000/μL or lymphocyte count \< 1000/μL;~* Infection requiring antibiotic treatment within the previous 4 weeks prior to screening;~* Participated in any clinical study of an investigational product within 30 days prior to screening or within 5 half-lives after taking the last dose;~* History or presence of any medical condition or disease which, in the opinion of the Investigator may place the subject at unacceptable risk for study participation;~* Inability to understand the potential risks and benefits of the study;~* Legal incapacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CCX168 (Type: EXPERIMENTAL): Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).